In vitro data suggest that the transfer of allogeneic Treg cells41 or specifically increasing brain-resident Treg cell numbers with an interleukin-2 (IL-2):IL-2 antibody72 or astrocyte-targeted gene delivery of IL-273 can protect against neuroinflammation and improve long-term stroke recovery. Here, IL2 is linked to Stroke.